Statins and stroke: Prevention and beyond

Current Opinion in Neurology

Volumn 24, Issue 1, 2011, Pages 75-80

  Prinz, Vincent ^a,b   Endres, Matthias ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Center for Stroke Research Berlin   (Germany)

Author keywords

endothelial function; prevention; statins; stroke; stroke outcome; vascular protection

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANTIOXIDANT ACTIVITY; BIOAVAILABILITY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; IMMUNOMODULATION; NEUROPROTECTION; NONHUMAN; PREMEDICATION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ANIMALS; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEUROPROTECTIVE AGENTS; STROKE; TREATMENT OUTCOME;

EID: 78651385719     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283424c53     Document Type: Review

References (50)

1. Donnan GA, Fisher M, Macleod M, et al. Stroke. Lancet 2008; 371:1612-1623.
2. Amarenco P, Moskowitz MA. The dynamics of statins: from event prevention to neuroprotection. Stroke 2006; 37:294-296.
3. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8:453-463.
4. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370:1829-1839.
5. Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005; 25:1093-1110.
6. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
7. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
8. Laufs U, Hoppe UC, Rosenkranz S, et al. Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society. Nervenarzt 2010; 81:444-462.
9. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39:1647-1652.
10. Lindsay P, Bayley M, McDonald A, et al. Toward a more effective approach to stroke: Canadian Best Practice Recommendations for Stroke Care. CMAJ 2008; 178:1418-1425.
11. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781-1790.
12. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97 (8A):69C-76C.
13. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97 (8A):77C-81C.
14. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995; 346:1647-1653.
15. Imamura T, Doi Y, Arima H, et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2009; 40:382-388.
16. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376:112-123.
17. Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902-2909.
18. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
20. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40:1405-1409.
21. Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 2009; 72:688-694.
22. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
23. Goldstein LB. JUPITER and the world of stroke medicine. Lancet Neurol 2009; 8:129-131.
24. Bosel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005; 92:1386-1398.
25. Laufs U, Gertz K, Dirnagl U, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002; 942 (1-2):23-30.
26. Prinz V, Laufs U, Gertz K, et al. Intravenous Rosuvastatin for Acute Stroke Treatment: an animal study. Stroke 2008; 39:433-438.
27. Kilic U, Bassetti CL, Kilic E, et al. Postischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular- regulated kinase-1/-2. Neuroscience 2005; 134:901-906.
28. Endres M, Laufs U. The medical case for the development of an intravenous statin formulation: beyond ischemic stroke. Cerebrovasc Dis 2008; 25:593-594.
29. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53:743-751.
30. Zhang L, Chopp M, Jia L, et al. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab 2009; 29:1816-1824.
31. Lee SH, Kim YH, Kim YJ, et al. Atorvastatin enhances hypothermia-induced neuroprotection after stroke. J Neurol Sci 2008; 275 (1-2):64-68.
32. Shehadah A, Chen J, Cui X, et al. Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome. J Neurol Sci 2010; 294 (1-2):107-111.
33. Lapchak PA, Han MK. Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. Brain Res 2010; 1344:217-225.
34. Rodriguez-Yanez M, Castellanos M, Blanco M, et al. Vascular protection in brain ischemia. Cerebrovasc Dis 2006; 21 (Suppl 2):21-29.
35. Elkind MS, Flint AC, Sciacca RR, et al. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005; 65:253-258.
36. Marti-Fabregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35:1117-1121.
37. Moonis M, Kane K, Schwiderski U, et al. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005; 36:1298-1300.
38. Arboix A, Garcia-Eroles L, Oliveres M, et al. Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? BMC Neurol 2010; 10:47.
39. Miedema I, Uyttenboogaart M, Koopman K, et al. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke. Cerebrovasc Dis 2010; 29:263-267.
40. Alvarez-Sabin J, Huertas R, Quintana M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke 2007; 38:1076-1078.
41. Goldstein LB, Amarenco P, Zivin J, et al. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009; 40:3526-3531.
42. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106:1690-1695.
43. Kennedy J, Hill MD, Ryckborst KJ, et al. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6:961-969.
44. Montaner J, Chacon P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008; 15:82-90.
45. Elkind MS, Sacco RL, Macarthur RB, et al. High-dose lovastatin for acute ischemic stroke: results of the Phase I Dose Escalation Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART). Cerebrovasc Dis 2009; 28:266-275.
46. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 2006; 37:2640-2643.
47. Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34:551-557.
48. Westphal S, Abletshauser C, Luley C. Fluvastatin treatment and withdrawal: effects on endothelial function. Angiology 2008; 59:613-618.
49. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69:904-910.
50. Laufs U, Rettig-Ewen V, Bohm M. Strategies to improve drug adherence. Eur Heart J 2010 [Epub ahead of print].